Related Experiment Video
Updated: Feb 5, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Profile of abemaciclib and its potential in the treatment of breast cancer
James M Martin1, Lori J Goldstein2
1Department of Medicine, Section of Hematology/Oncology, Temple University Hospital, Philadelphia, PA, USA, james.martin2@tuhs.temple.edu.
Abstract:
Hormone-receptor-positive breast cancer is the most common subtype of breast cancer among patients with both early-stage and metastatic disease. Recent advances in the understanding of its pathophysiology have led to the discovery and utilization of targeted inhibitors to cyclin-dependent kinases 4 and 6 (CDK4/6). There are currently three available CDK4/6 inhibitors available for use in USA: palbociclib, ribociclib, and abemaciclib. Their oral administration and tolerable toxicities make this class of agents appealing to both patients and health care providers. Abemaciclib, the most recently approved CDK4/6 inhibitor, has unique pharmacologic properties and potential toxicities. This review highlights the current understanding of abemaciclib and discusses its current and future roles in the treatment of breast cancer.
Insights
Abemaciclib is a targeted therapy for hormone-receptor-positive breast cancer. This review details its unique properties and role in treating breast cancer patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Hormone-receptor-positive breast cancer is the most common subtype.
- Targeted inhibitors for cyclin-dependent kinases 4 and 6 (CDK4/6) represent a significant advancement.
Purpose of the Study:
- To review the current understanding of abemaciclib.
- To discuss the current and future roles of abemaciclib in breast cancer treatment.
Main Methods:
- Literature review of abemaciclib's pharmacologic properties and clinical data.
- Analysis of abemaciclib's unique toxicities and therapeutic applications.
Main Results:
- Abemaciclib is the most recently approved CDK4/6 inhibitor.
- It possesses unique pharmacologic properties and potential toxicities.
- Oral administration and tolerable toxicities make CDK4/6 inhibitors appealing.
Conclusions:
- Abemaciclib offers a new targeted treatment option for breast cancer.
- Further research will define its optimal role in various treatment settings.
- Understanding its unique profile is crucial for effective clinical use.
Related Concept Videos
Treatment Resistant Cancers
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Potential Energy
Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
Standard Electrode Potentials
Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...

